Page last updated: 2024-11-03

proxymetacaine and Diabetes Mellitus, Type 2

proxymetacaine has been researched along with Diabetes Mellitus, Type 2 in 1 studies

proxymetacaine: RN given refers to parent cpd; structure

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, YH1
Kim, YS1
Park, CH1
Chung, IY1
Yoo, JM1
Kim, JG1
Lee, BJ1
Kang, SS1
Cho, GJ1
Choi, WS1

Other Studies

1 other study available for proxymetacaine and Diabetes Mellitus, Type 2

ArticleYear
Protein kinase C-delta mediates neuronal apoptosis in the retinas of diabetic rats via the Akt signaling pathway.
    Diabetes, 2008, Volume: 57, Issue:8

    Topics: Acetophenones; Animals; Apoptosis; Benzopyrans; Body Weight; Diabetes Mellitus, Type 2; HSP90 Heat-S

2008